webleads-tracker

Conflicts of interests, transparency, transparence des liens d'intérêts, sunshine act, loi bertrand

EMA policy on the handling of competing interests of scientific committees’ members and experts

EU legislation clearly states that the members of the scientific committees and experts shall not have financial or other interests in the pharmaceutical industry that could affect their impartiality.Pharma Compliance Digital CRM Marketing Transparence DMOS Europe map 200 EMA policy on the handling of  competing  interests of scientific committees’ members  and experts
They shall make an annual declaration of their financial interests. In addition, all indirect interests which could relate to the pharmaceutical industry shall be entered in a register held by the European Medicines Agency (referred to in this document as “Agency”), which is accessible to the public, on request, at the Agency’s offices.
The Agency’s Code of Conduct provides general guidance on several aspects related to declarations of interests. Information is made available about what should be declared by whom and at what moment in time. In addition, clarification about some operational aspects is given by stating the tasks of the Agency’s secretariat, the obligations of the individuals concerned and the meeting proceedings.

Check Also

Le Sunshine Act Belge – Belgium Sunshine Act

CHAPITRE 1er. – Sunshine act Art. 41. § 1er. Pour l’application du présent chapitre, on …